Inovio's CELLECTRAA Electroporation Delivery Technology Powers Durable, Best-in-Class T-Cell Responses from HIV Vaccine in Human Study

Inovio Pharmaceuticals, Inc. announced today the peer-reviewed publication of results from two phase I trials of its PENNVAX -B preventive HIV DNA vaccine delivered with a DNA adjuvant and with or without Inovio's proprietary CELLECTRA electroporation delivery device.

http://www.freshnews.com/news/819524/inovio-s-cellectra-electroporation-delivery-technology-powers-durable-best-class-t-cell